Handelsavisen
prelaunch
Companies ›Healthcare ›IMNM.O
IM
IMNM.O — NASDAQ Biotechnology

Imnm.O

$22,94
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-3 228,8 %
ROE
-33,5 %
Net margin
-3 060,0 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$23,11
Open
—
Next earnings
2026-08-05
Ex-dividend
—
TR 1Y
—
About

Immunome Inc. is a biotechnology company operating within the Health Care sector, though specific business activities and revenue generation mechanisms are not detailed in the available data.

Business. Immunome Inc. is a biotechnology company operating within the Health Care sector, though specific business activities and revenue generation mechanisms are not detailed in the available data.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ2 2026 earnings (expected)2026-08-05 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
-33,5 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning IMNM.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to IMNM.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ2 2026 earnings (expected)2026-08-05 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Immunome Inc. is a biotechnology company operating within the Health Care sector, though specific business activities and revenue generation mechanisms are not detailed in the available data.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    (a) Immunome Inc. maintains a strong liquidity position with cash and equivalents of $653.5 million against total liabilities of $48.8 million, resulting in a debt-to-equity ratio of 0.0. The company holds total equity of $634.3 million, providing a substantial buffer against its current operational cash burn.

    (b) The company is currently unprofitable, reporting a net income loss of $212.4 million and an operating income loss of $224.1 million. Return on equity stands at -33.48% and return on assets at -31.09%, indicating significant capital erosion relative to the asset base. Revenue is minimal at $6.9 million, suggesting the company is in a pre-commercial or early-stage development phase.

    Key takeaways
    • Strong balance sheet with $653.5 million in cash and zero debt provides significant runway despite operational losses.
    • High burn rate with $224.1 million in operating losses and $190.9 million in negative operating cash flow.
    • Minimal revenue of $6.9 million suggests the company is not yet generating significant commercial sales.
    • Low dilution and liquidity risk flags indicate no immediate distress in capital structure.
    • Lack of segment, geographic, and historical data limits deeper fundamental analysis.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $22,94
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $634.3M
    Net cashⓘ
    $653.5M
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    -31.1%
    ROEⓘ
    -33.5%
    Cash conversionⓘ
    90.0%
    CapEx / revenueⓘ
    1.4%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution14 analysts
    Strong buy3
    Buy11
    Hold0
    Sell0
    Strong sell0
    12-month price target$35,50 · Median $35,50
    Low $30,00High $40,00
    Operating income · consensus-263,3M USD
    EPS surprise
    −12,5 %
    reported vs consensus · miss
    Revenue surprise
    +155,5 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$30,00
    Mean$35,50
    Median$35,50
    High$40,00
    Spot$22,94
    +54.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-3 228,8 %Bottom quartile
    Net Margin-3 060,0 %Bottom quartile
    ROE-33,5 %Below median
    Capex / Rev139,5 %Best in class
    D/E0,00Above median
    Cash Conv0,90Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 649 229 sh7 exercises · 13 grants13 insiders
    • SIEGALL CLAY BDirector, President and CEO · Employee Stock Option (right to buy) → Common StockAcquired 360 000 @ $22,01grant · 2026-07-23
    • Rosett MaxChief Financial Officer · Employee Stock Option (right to buy) → Common StockAcquired 94 500 @ $22,01grant · 2026-07-23
    • Tsai PhilipChief Technical Officer · Employee Stock Option (right to buy) → Common StockAcquired 76 500 @ $22,01grant · 2026-07-23
    • Horn KinneyCHIEF BUSINESS OFFICER · Employee Stock Option (right to buy) → Common StockAcquired 62 500 @ $22,01grant · 2026-07-23
    • Stoneman Sandra G.CHIEF LEGAL OFFICER & GC · Employee Stock Option (right to buy) → Common StockAcquired 76 500 @ $22,01grant · 2026-07-23
    • Higgins JackChief Scientific Officer · Employee Stock Option (right to buy) → Common StockAcquired 76 500 @ $22,01grant · 2026-07-23
    • Lechleider RobertChief Medical Officer · Employee Stock Option (right to buy) → Common StockAcquired 108 000 @ $22,01grant · 2026-07-23
    • Horn KinneyCHIEF BUSINESS OFFICER · Employee Stock Option (right to buy) → Common StockDisposed 1 092 @ $12,92exercise · 2026-07-07
    • Lechleider RobertChief Medical Officer · Employee Stock Option (right to buy) → Common StockDisposed 55 000 @ $8,73exercise · 2026-07-02
    • Lechleider RobertChief Medical Officer · Employee Stock Option (right to buy) → Common StockDisposed 55 000 @ $8,73exercise · 2026-06-25
    • Rosett MaxChief Financial Officer · Stock Option (right to buy) → Common StockDisposed 60 000 @ $1,05exercise · 2026-06-15
    • WAGENHEIM PHILIPDirector · Director Stock Option (right to buy) → Common StockAcquired 9 897 @ $18,16grant · 2026-06-10
    • Barchas IsaacDirector · Director Stock Option (right to buy) → Common StockAcquired 9 897 @ $18,16grant · 2026-06-10
    • SCHAFER CAROLDirector · Director Stock Option (right to buy) → Common StockAcquired 9 897 @ $18,16grant · 2026-06-10
    • Boylan James PDirector · Director Stock Option (right to buy) → Common StockAcquired 9 897 @ $18,16grant · 2026-06-10
    • SWAIN SANDRA MDirector · Director Stock Option (right to buy)` → Common StockAcquired 9 897 @ $18,16grant · 2026-06-10
    • BIENAIME JEAN JACQUESDirector · Director Stock Option (right to buy) → Common StockAcquired 9 897 @ $18,16grant · 2026-06-10
    • Rosett MaxChief Financial Officer · Stock option (right to buy) → Common StockDisposed 31 848 @ $1,05exercise · 2026-04-02
    • Rosett MaxChief Financial Officer · Stock option (right to buy) → Common StockDisposed 39 713 @ $1,35exercise · 2026-04-02
    • Higgins JackChief Scientific Officer · Employee Stock option (right to buy) → Common StockDisposed 22 000 @ $1,35exercise · 2025-09-10

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Capex To Revenue
      capital_expenditure / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    Source documents
    • Immunome, Inc. Market data — financials · 2026-07-30
    • reconciler_enqueue (reconciler) on IMNM.O · 2026-07-30

    Ownership & reference

    Top holders

    • T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,25 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,02 %$371M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,02 %$103M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,02 %$30M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,01 %$18M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,01 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$118M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$62M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$56M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$24M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$19M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$20M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$130M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$9M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$4M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$6M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$45M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$3M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$2M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$2M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Purnanand D. SarmaPresident, Chief Executive Officer, Director

    Insider activity

    Net selling11 buys · 21 sellsnet -$19,5M10 insiders · last 365d
    • Horn KinneyCHIEF BUSINESS OFFICER · Common StockOther 31 250 · 2026-07-23
    • Rosett MaxChief Financial Officer · Common StockOther 47 250 · 2026-07-23
    • Lechleider RobertChief Medical Officer · Common StockOther 54 000 · 2026-07-23
    • SIEGALL CLAY BDirector, President and CEO · Common StockOther 180 000 · 2026-07-23
    • Stoneman Sandra G.CHIEF LEGAL OFFICER & GC · Common StockOther 38 250 · 2026-07-23
    • Tsai PhilipChief Technical Officer · Common StockOther 38 250 · 2026-07-23
    • Higgins JackChief Scientific Officer · Common StockOther 38 250 · 2026-07-23
    • Horn KinneyCHIEF BUSINESS OFFICER · Common StockSold 1 092 @ $25,00$27K · 2026-07-07
    • Horn KinneyCHIEF BUSINESS OFFICER · Common StockOther 1 092 @ $12,92$14K · 2026-07-07
    • Barchas IsaacDirector · Common StockSold 16 906 @ $24,20$409K · 2026-07-07
    • Barchas IsaacDirector · Common StockSold 83 094 @ $24,11$2,0M · 2026-07-06
    • Lechleider RobertChief Medical Officer · Common StockSold 16 072 @ $23,44$377K · 2026-07-02
    • Lechleider RobertChief Medical Officer · Common StockOther 55 000 @ $8,73$480K · 2026-07-02
    • Lechleider RobertChief Medical Officer · Common StockSold 22 714 @ $21,95$499K · 2026-07-02
    • Lechleider RobertChief Medical Officer · Common StockSold 16 214 @ $22,76$369K · 2026-07-02
    • Barchas IsaacDirector · Common StockSold 24 335 @ $23,33$568K · 2026-07-02
    • Barchas IsaacDirector · Common StockSold 75 665 @ $22,35$1,7M · 2026-07-02
    • Barchas IsaacDirector · Common StockSold 101 050 @ $21,12$2,1M · 2026-06-30
    • Lechleider RobertChief Medical Officer · Common StockSold 14 420 @ $20,66$298K · 2026-06-25
    • Lechleider RobertChief Medical Officer · Common StockSold 40 580 @ $19,56$794K · 2026-06-25
    • Lechleider RobertChief Medical Officer · Common StockOther 55 000 @ $8,73$480K · 2026-06-25
    • Rosett MaxChief Financial Officer · Common StockSold 60 000 @ $18,23$1,1M · 2026-06-15
    • Rosett MaxChief Financial Officer · Common StockOther 60 000 @ $1,05$63K · 2026-06-15
    • BIENAIME JEAN JACQUESDirector · Common StockSold 500 @ $19,44$10K · 2026-06-05
    • BIENAIME JEAN JACQUESDirector · Common StockSold 10 000 @ $19,41$194K · 2026-06-05

    Short positioning

    17.2Mshares short-0.7% vs prior
    10.54days to cover
    43.2%short of daily vol
    4.1Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    IMNM.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Shares outstanding (annual): 113.13MUnknown
    • R&D expense (annual): USD 177.29MUnknown
    • Cash & equivalents (annual): USD 653.48MUnknown
    • Current liabilities (annual): USD 44.99MUnknown
    • Total operating expenses (annual): USD 231.05MUnknown
    • Total assets (annual): USD 683.19MUnknown
    • Net income (annual): USD -212.39MUnknown
    • Capex (annual): USD 9.69MUnknown
    • Operating income (annual): USD -224.11MUnknown
    • Revenue (annual): USD 6.94MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -2Unknown
    • EPS (diluted) (annual): USD-PER-SHARES -2Unknown
    • Operating cash flow (annual): USD -190.92MUnknown
    • Shareholders' equity (annual): USD 634.34MUnknown
    • Total liabilities (annual): USD 48.84MUnknown
    • Current assets (annual): USD 660.78MUnknown
    • R&D expense (annual): USD 129.54MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -5Unknown
    • Current liabilities (annual): USD 54.31MUnknown
    • Shares outstanding (annual): 64.46MUnknown
    • Cash & equivalents (annual): USD 143.35MUnknown
    • Total liabilities (annual): USD 59.08MUnknown
    • Capex (annual): USD 7.17MUnknown
    • Total operating expenses (annual): USD 314.84MUnknown
    Showing 24 of 32 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-05 00:00 UTCTRANSCRIPTUpcomingEarnings call — Q3 2026
    2026-08-05EVENTUpcomingQ2 2026 earnings (expected) estimated date
    2026-07-23INSIDERHorn Kinney transacted 31.2k sh — CHIEF BUSINESS OFFICER
    2026-07-23INSIDERRosett Max transacted 47.2k sh — Chief Financial Officer
    2026-07-23INSIDERLechleider Robert transacted 54.0k sh — Chief Medical Officer
    2026-07-23INSIDERSIEGALL CLAY B transacted 180.0k sh — Director, President and CEO
    2026-07-23INSIDERStoneman Sandra G. transacted 38.2k sh — CHIEF LEGAL OFFICER & GC
    2026-07-23INSIDERTsai Philip transacted 38.2k sh — Chief Technical Officer
    2026-07-23INSIDERHiggins Jack transacted 38.2k sh — Chief Scientific Officer
    2026-07-23INSIDERRosett Max acquired 94.5k sh Employee Stock Option (right to buy) — Chief Financial Officer
    2026-07-23INSIDERHiggins Jack acquired 76.5k sh Employee Stock Option (right to buy) — Chief Scientific Officer
    2026-07-23INSIDERSIEGALL CLAY B acquired 360.0k sh Employee Stock Option (right to buy) — Director, President and CEO
    2026-07-23INSIDERStoneman Sandra G. acquired 76.5k sh Employee Stock Option (right to buy) — CHIEF LEGAL OFFICER & GC
    2026-07-23INSIDERTsai Philip acquired 76.5k sh Employee Stock Option (right to buy) — Chief Technical Officer
    2026-07-23INSIDERHorn Kinney acquired 62.5k sh Employee Stock Option (right to buy) — CHIEF BUSINESS OFFICER
    2026-07-23INSIDERLechleider Robert acquired 108.0k sh Employee Stock Option (right to buy) — Chief Medical Officer
    2026-07-07INSIDERHorn Kinney sold 1.1k sh — CHIEF BUSINESS OFFICER ~$27k
    2026-07-07INSIDERHorn Kinney transacted 1.1k sh — CHIEF BUSINESS OFFICER ~$14k
    2026-07-07INSIDERBarchas Isaac sold 16.9k sh — Director ~$409k
    2026-07-07INSIDERHorn Kinney disposed of 1.1k sh Employee Stock Option (right to buy) — CHIEF BUSINESS OFFICER
    2026-07-06INSIDERBarchas Isaac sold 83.1k sh — Director ~$2.00M
    2026-07-02INSIDERLechleider Robert sold 16.1k sh — Chief Medical Officer ~$377k
    2026-07-02INSIDERLechleider Robert transacted 55.0k sh — Chief Medical Officer ~$480k
    2026-07-02INSIDERLechleider Robert sold 22.7k sh — Chief Medical Officer ~$499k
    2026-07-02INSIDERLechleider Robert sold 16.2k sh — Chief Medical Officer ~$369k
    2026-07-02INSIDERBarchas Isaac sold 24.3k sh — Director ~$568k
    2026-07-02INSIDERBarchas Isaac sold 75.7k sh — Director ~$1.69M
    2026-07-02INSIDERLechleider Robert disposed of 55.0k sh Employee Stock Option (right to buy) — Chief Medical Officer
    2026-06-30INSIDERBarchas Isaac sold 101.0k sh — Director ~$2.13M
    2026-06-25 00:00 UTCINSIDER18 insider transactions — 2026-06 · net sell $1.6M 8 derivative
    2026-06-25 00:00 UTCINSIDER18 insider transactions — 2026-06 · net sell $1.6M 8 derivative
    2026-06-25INSIDERLechleider Robert sold 14.4k sh — Chief Medical Officer ~$298k
    2026-06-25INSIDERLechleider Robert sold 40.6k sh — Chief Medical Officer ~$794k
    2026-06-25INSIDERLechleider Robert transacted 55.0k sh — Chief Medical Officer ~$480k
    2026-06-25INSIDERLechleider Robert disposed of 55.0k sh Employee Stock Option (right to buy) — Chief Medical Officer
    2026-06-15INSIDERRosett Max sold 60.0k sh — Chief Financial Officer ~$1.09M
    2026-06-15INSIDERRosett Max transacted 60.0k sh — Chief Financial Officer ~$63k
    2026-06-15INSIDERRosett Max disposed of 60.0k sh Stock Option (right to buy) — Chief Financial Officer
    2026-06-12FILING8-K filing →
    2026-06-10INSIDERSWAIN SANDRA M acquired 9.9k sh Director Stock Option (right to buy)` — Director
    Showing the 40 most recent of 62 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage